Lung cancer genomics and bioinformatics

Alterations in the genome play a central role in the development and progression of lung cancer. Inherited genetic variants may increase an individuals susceptibility to the disease and mutations acquired in the lung during ones lifetime (for example, through exposure to cigarette smoke) contribute to disease onset, particularly if these occur in oncogenes or tumour suppressor genes.

Recent improvements in high-throughput technologies (for example, DNA sequencing and mRNA/miRNA expression profiling) mean that lung tumour samples can be analysed in greater depth than ever before. As part of the European FP7 projects, cure lung and LCaos we are analysing a number of lung tumours at the genomic level. The aims of these studies are twofold, firstly to provide insight into lung cancer biology and secondly to develop and improve upon current lung cancer risk-assessment strategies and biomarkers (for early detection, prognosis or directed treatment). Regarding the latter, we have recently developed a prognostic expression signature from lung squamous cell carcinoma and adenocarcinoma samples [1] in collaboration with Professor Andy Brass.

Additionally, the Liverpool Lung Project is contributing to international efforts to elucidate the roles of genetics and genomics in inherited lung cancer risk and in tumourigenesis  [2]

[1] - Han N et al, Int. J. Oncol. (2012) 41:242-52
[2] - Peifer M. et al Nat. Genet. (2012) 44:1104-10 



Professor John K. Field
Research Director

Tel:  0151 794 9113

Dr Triantafillos Liloglou
Lecturer, Biomarkers and Clinical Resources Group

Tel:  0151 794 9121


Designed & Developed By: AN Computing